Windlas Biotech Limited (BOM:543329)
India
· Delayed Price · Currency is INR 915.65
-2.80 (-0.30%)
At close: Jun 6, 2025
Windlas Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2018 - 2020 |
| Revenue | 7,599 | 6,310 | 5,131 | 4,659 | 4,276 | Upgrade
|
| Revenue Growth (YoY) | 20.43% | 22.97% | 10.12% | 8.96% | 30.03% | Upgrade
|
| Cost of Revenue | 4,719 | 4,004 | 3,296 | 3,079 | 2,791 | Upgrade
|
| Gross Profit | 2,880 | 2,305 | 1,835 | 1,581 | 1,485 | Upgrade
|
| Selling, General & Admin | 1,229 | 927.74 | 736.88 | 656.86 | 596.43 | Upgrade
|
| Other Operating Expenses | 710 | 595.94 | 495.85 | 399.53 | 324.41 | Upgrade
|
| Operating Expenses | 2,219 | 1,658 | 1,356 | 1,178 | 1,050 | Upgrade
|
| Operating Income | 661.22 | 647.28 | 478.7 | 402.76 | 434.14 | Upgrade
|
| Interest Expense | -43.82 | -11.05 | -7.88 | -14.17 | -12.9 | Upgrade
|
| Interest & Investment Income | - | 19.69 | 34.9 | 42.85 | 19.21 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -1.73 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 3.23 | 3.82 | 4.77 | 1.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 180.18 | 3.49 | 4.35 | 0.77 | 1.98 | Upgrade
|
| EBT Excluding Unusual Items | 797.58 | 662.64 | 513.89 | 436.98 | 441.73 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -272.64 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 108.21 | 47.82 | 18.57 | 62.22 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.06 | 8.76 | 0.1 | 0.09 | Upgrade
|
| Asset Writedown | - | - | -0.08 | - | -14 | Upgrade
|
| Pretax Income | 797.58 | 770.91 | 570.39 | 455.65 | 217.4 | Upgrade
|
| Income Tax Expense | 187.64 | 189.04 | 144.13 | 74.76 | 61.7 | Upgrade
|
| Earnings From Continuing Operations | 609.94 | 581.87 | 426.26 | 380.89 | 155.7 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 2.62 | Upgrade
|
| Net Income | 609.94 | 581.87 | 426.26 | 380.89 | 158.32 | Upgrade
|
| Net Income to Common | 609.94 | 581.87 | 426.26 | 380.89 | 158.32 | Upgrade
|
| Net Income Growth | 4.82% | 36.51% | 11.91% | 140.58% | -2.35% | Upgrade
|
| Shares Outstanding (Basic) | 21 | 21 | 22 | 20 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 21 | 22 | 20 | 18 | Upgrade
|
| Shares Change (YoY) | 1.22% | -3.53% | 5.56% | 12.58% | - | Upgrade
|
| EPS (Basic) | 29.19 | 27.97 | 19.70 | 18.58 | 8.70 | Upgrade
|
| EPS (Diluted) | 28.87 | 27.88 | 19.70 | 18.58 | 8.70 | Upgrade
|
| EPS Growth | 3.55% | 41.52% | 6.03% | 113.68% | -2.30% | Upgrade
|
| Free Cash Flow | 159.93 | 712.76 | -99.25 | -56.74 | 56.07 | Upgrade
|
| Free Cash Flow Per Share | 7.57 | 34.15 | -4.59 | -2.77 | 3.08 | Upgrade
|
| Dividend Per Share | 5.800 | 5.500 | 4.000 | 3.500 | - | Upgrade
|
| Dividend Growth | 5.46% | 37.50% | 14.29% | - | - | Upgrade
|
| Gross Margin | 37.90% | 36.54% | 35.77% | 33.92% | 34.72% | Upgrade
|
| Operating Margin | 8.70% | 10.26% | 9.33% | 8.64% | 10.15% | Upgrade
|
| Profit Margin | 8.03% | 9.22% | 8.31% | 8.18% | 3.70% | Upgrade
|
| Free Cash Flow Margin | 2.10% | 11.30% | -1.93% | -1.22% | 1.31% | Upgrade
|
| EBITDA | 941.07 | 762.1 | 586.88 | 515.48 | 552.26 | Upgrade
|
| EBITDA Margin | 12.38% | 12.08% | 11.44% | 11.06% | 12.91% | Upgrade
|
| D&A For EBITDA | 279.85 | 114.82 | 108.18 | 112.72 | 118.12 | Upgrade
|
| EBIT | 661.22 | 647.28 | 478.7 | 402.76 | 434.14 | Upgrade
|
| EBIT Margin | 8.70% | 10.26% | 9.33% | 8.64% | 10.15% | Upgrade
|
| Effective Tax Rate | 23.53% | 24.52% | 25.27% | 16.41% | 28.38% | Upgrade
|
| Revenue as Reported | 7,779 | 6,444 | 5,230 | 4,726 | 4,307 | Upgrade
|
| Advertising Expenses | - | 48.32 | 29.75 | 18.4 | 12.79 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.